Home › Exocrine Pancreatic Insufficiency › NCT07285863

A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects

An Open-Label Study On The Effects Of Human Secretin For Injection (CHIROSTIM) On Pancreatic Fluid Composition In Normal Human Volunteer Participants

Who can join

Ages 18 to 80 · All sexes · Healthy volunteers welcome

Inclusion Criteria

* Males or non-pregnant females
* Age 18-80.
* Participants must be in good health based on medical history (ASA Class 3 or below)
* Participants must be willing and able to provide informed consent
* Receiving an endoscopic ultrasound for a non-pancreatic indication

Exclusion Criteria

* History of any form of pancreatitis and/or other pancreatic diseases (e.g. pancreatic cysts, pancreatic masses).
* History of inflammatory bowel disease
* History of vagotomy.
* History of surgically altered upper gastrointestinal anatomy (e.g. gastric bypass, Billroth I/II)
* History of liver disease
* Pregnant women or nursing mothers
* Regular use of anticholinergics
* \> 2 drinks of alcohol daily
* Smokers (cigarette)

About the study

The purpose of this study is to collect pancreas fluid from the duodenum using the endoscopic pancreas function collection method in healthy participants after pancreatic stimulation with human secretin.

What is being tested

• Secretin (human synthetic) - ChiRhoClin (drug)

Sponsor: Mayo Clinic · Participants: 24 · Started: Mar 11, 2026

Contact the study team

• Liz Lemke · Phone: 507-266-3317

Official record on ClinicalTrials.gov — NCT07285863

Locations in the U.S.

Conditions

• Exocrine Pancreatic Insufficiency
• Chronic Pancreatitis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.